¹⁸F-NaF PET-CT versus ^99mTc SPECT in bone metastasis assessment

Affiliations

¹ Clinical and Technical Support, Philips Healthcare, Beijing, China. Electronic address: jiazheng.wang@philips.com.
² Department of Radiology, University College London Hospital, London, UK.

Comment

Jiazheng Wang et al. Lancet Oncol. 2023 Feb.

. 2023 Feb;24(2):e68.

doi: 10.1016/S1470-2045(23)00003-7.

¹ Clinical and Technical Support, Philips Healthcare, Beijing, China. Electronic address: jiazheng.wang@philips.com.
² Department of Radiology, University College London Hospital, London, UK.

No abstract available

Conflict of interest statement

We declare no competing interests.

¹⁸F-NaF PET-CT versus ^99mTc SPECT in bone metastasis assessment - Authors' reply.
Bénard F, Harsini S. Bénard F, et al. Lancet Oncol. 2023 Feb;24(2):e69. doi: 10.1016/S1470-2045(23)00017-7. Lancet Oncol. 2023. PMID: 36725149 No abstract available.

Intra-individual comparison of ¹⁸F-sodium fluoride PET-CT and ^99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial.
Bénard F, Harsini S, Wilson D, Zukotynski K, Abikhzer G, Turcotte E, Cossette M, Metser U, Romsa J, Martin M, Mar C, Saad F, Soucy JP, Eigl BJ, Black P, Krauze A, Burrell S, Nichol A, Tardif JC. Bénard F, et al. Lancet Oncol. 2022 Dec;23(12):1499-1507. doi: 10.1016/S1470-2045(22)00642-8. Epub 2022 Nov 4. Lancet Oncol. 2022. PMID: 36343655 Clinical Trial.